Sonnet Biotherapeutics

SONN

US83548R4020

Delayed Nasdaq Other stock markets 04:00:00 2025-12-02 pm EST			5-day change	1st Jan Change
1.260 ^USD	-59.35%		-66.13%	-13.70%

Dec. 02	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Dec. 02	Top Midday Decliners	MT

Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies

Published on 12/02/2025 at 09:43 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sonnet Biotherapeutics

Dec. 02	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Dec. 02	Top Midday Decliners	MT
Dec. 02	Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies	RE
Dec. 01	Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index	CI
Dec. 01	Hyperliquid Strategies Inc completed the acquisition of Sonnet BioTherapeutics Holdings, Inc. in a reverse merger transaction.	CI
Oct. 15	Sonnet BioTherapeutics Holdings, Inc. Collaborates with Spanishos on Non-Clinical Study Using New Alternate Methodologies Based Patient-Derived Tumoroid Platform	CI
Sep. 15	Top Premarket Decliners	MT
Aug. 13	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
Aug. 11	Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer	CI
Aug. 04	Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study	MT
Aug. 04	Sonnet Biotherapeutics expands trial of SON-1010 with atezolizumab in advanced ovarian cancer	RE
Aug. 04	Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	CI
Jul. 15	Top Premarket Decliners	MT
Jul. 14	Sector Update: Health Care Stocks Edge Down Late Afternoon	MT
Jul. 14	Top Midday Gainers	MT
Jul. 14	Atlas Merchant Capital LLC entered into a definitive agreement to acquire Sonnet BioTherapeutics Holdings, Inc. in a reverse merger transaction.	CI
Jul. 14	Traders Digest Tariff Announcements, Driving Premarket Losses for US Equity Futures	MT
Jul. 14	Top Premarket Gainers	MT
Jul. 14	Sonnet Biotherapeutics, Inc Announces $888 Million Business Combination with Rorschach I LLC to Create Entity to Be Named Hyperliquid Strategies Inc	CI
Jul. 14	Sonnet Biotherapeutics, Inc. announces $888 million business combination to launch a hype cryptocurrency treasury reserve strategy	RE
Jul. 14	Sonnet to Merge With Rorschach, Form $888M Crypto Treasury Firm Hyperliquid Strategies	MT
Jul. 13	Sonnet BioTherapeutics Holdings, Inc. announces tranche update	CI
Jul. 10	Sonnet BioTherapeutics Holdings, Inc. announced that it expects to receive $310.23499 million in funding	CI
Jul. 07	Top Premarket Gainers	MT
Jul. 03	Wall Street Set to Open Higher Thursday as Jobs Data Tops Forecasts	MT

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Employees

Sector

More about the company